Ranked 9th! Guorui Biotech ranks among the forefront of China's CDMO enterprises in 2022

From December 9th to 10th, the 2022 Health Industry High-quality Development Conference and the 7th China Pharmaceutical R&D and Innovation Summit (PDI Conference), hosted by the Organizing Committee of China International Intelligent Industry Expo and organized by Chongqing Nan'an District People's Government, Chongqing Economic and Technological Development Zone Management Committee, PharmaSmart Network and China Pharmaceutical Magazine, opened online. At this conference, led by academicians, top scientists, scientific research and enterprise experts in the field of Chinese medicine gathered together, focusing on product strategy and deepening R&D pipelines, and discussing the future of China's biomedical development, which can be described as an annual high-end summit of industry influence!

On the first day of the conference, the list of "2022 China's Top 20 CDMO Enterprises" was released, and Hangzhou Guorui Biotechnology Co., Ltd. stood out from hundreds of biopharmaceutical companies and ranked ninth on the list with its strong R&D strength and rich scientific research achievements. As a national high-tech enterprise, Guorui Biotech deserves to win this award!

This is also after winning many honorary titles such as "National High-tech Enterprise", "National Science and Technology Small and Medium-sized Enterprise", "Zhejiang Science and Technology Small and Medium-sized Enterprise", "Zhejiang Enterprise High-tech Research and Development Center", "Hangzhou Enterprise High-tech Research and Development Center", "Hangzhou Young Eagle Plan Enterprise", "Hangzhou High-tech Zone Gazelle Enterprise" and many other honorary titles, Guorui Biotech once again included a heavyweight CDMO award, fully demonstrating the industry's high recognition and recognition of Guorui Biotechnology.

Trusted CDMO & CRO supplier

Founded in 2017 and headquartered in Wanlun Science and Technology Park, Binjiang District, Hangzhou, Guorui Biotech is a comprehensive medical technology R&D enterprise rooted in Binjiang, rapidly developing and growing, with small molecules and oligonucleotides as the main direction of drug development, research and industrialization.

Although Guorui Biotech is a young start-up, it has formed core competitive advantages in terms of technical team, drug R&D services, commercial production services, quality assurance system, etc., and strives to provide customers with "efficient, flexible and high-quality services", promises and guarantees process safety, production safety and intellectual property protection, and is known as a trusted CDMO & CRO supplier in the pharmaceutical field.

It is worth mentioning that Guorui Biotech has successful cases of cooperation with well-known large and medium-sized enterprises at home and abroad, and has accumulated rich experience in the research and application services of innovative drugs and generic drugs. The company has the ability to research and develop dosage forms such as tablets, injections, capsules, granules, oral liquid preparations, etc.

Low-key and rapid rise

In terms of team, Guorui Biotech has established professional and technical personnel including synthesis, quality, CRC, CRA, QA, registration, instrumentation, bioanalysis, device, statistics, data management and other links, and has successfully built a perfect drug research and development system and quality assurance system.

Its employees account for more than 40%, and the core employees are all from well-known pharmaceutical companies at home and abroad. The backbone of Guorui Biologics' CDMO business has the experience of well-known domestic outsourcing service pharmaceutical companies, has a deep understanding of CDMO service characteristics, and team members can quickly respond and provide project solutions with rich experience in process development, optimization and production. Guorui Biotech has established strategic partnerships with a number of domestic pharmaceutical factories and fine chemical enterprises with GMP certification, which can quickly complete the delivery of finished products such as pharmaceutical intermediates, APIs and preclinical new drugs from kilograms to tons.

The company has a 6,000㎡ R&D laboratory, equipped with various advanced experimental instruments and equipment, covering new drug research and development, API research and development, and the development and production of advanced intermediates of generic drugs. In addition, Guorui Biotech has a complete quality assurance system, with complete testing and analysis equipment, QC to establish a data integrity system, equipped with professional R&D QA, the entire quality research process in accordance with cGMP management, QC laboratory is preparing CMA/CNAS certification.

I believe that the present is the beginning of Guorui Biotechnology towards the sea of stars. On the CDMO track of biological drugs, Guorui Biotech will step into high-speed development and ride the wind and waves!